Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 12, 2017

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Solid Tumor, Adult
Interventions
PROCEDURE

research blood draws

Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER

NCT03302325 - Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC | Biotech Hunter | Biotech Hunter